Linked from

The 44 pages that link to Renin–angiotensin–aldosterone system, each with the reason it gives.

• HypertensionRelated: Its persistent activation can constrict vessels and raise blood pressure.

• Chronic kidney diseaseRelated: Its activation can raise pressure within glomeruli and accelerate kidney injury.

• Blood pressureRelated: Its slower hormonal actions help maintain pressure over hours to days.

• AldosteroneNarrower topic: This system is a major controller of aldosterone secretion when kidney perfusion or sodium delivery falls.

• Beta blockerRelated: Blocking beta-1 receptors in the kidney can reduce renin release and its downstream effects.

• Adrenal insufficiencyRelated: It helps explain why aldosterone regulation can remain intact when pituitary signaling fails.

• ACE inhibitorNarrower topic: ACE inhibitors interrupt this system between angiotensin I and angiotensin II.

• AscitesRelated: Its activation causes the kidneys to retain sodium and water as ascites advances.

• EicosanoidRelated: Eicosanoids interact with renal and vascular control systems that influence blood pressure.

• Adrenal cortexRelated: Angiotensin II is a principal signal for aldosterone production in the zona glomerulosa.

• Diabetic nephropathyRelated: Its intrarenal activity raises glomerular pressure and contributes to progressive injury.

• ProteinuriaRelated: Medicines that inhibit this system can reduce protein loss in many kidney diseases.

• BaroreflexCompared with: It supports pressure regulation over minutes to days, unlike the baroreflex's rapid neural action.

• Thiazide diureticRelated: Reduced circulating volume can activate this system during thiazide treatment.

• Adrenal glandRelated: It signals the adrenal cortex to adjust aldosterone secretion.

• Antidiuretic hormoneCompared with: It overlaps in fluid-balance outcomes but acts through a distinct regulatory system.

• Angiotensin-converting enzymeNarrower topic: ACE is a key step in the system’s production of angiotensin II.

• BradykininCompared with: ACE acts on both systems: it forms angiotensin II while degrading bradykinin.

• Primary aldosteronismNarrower topic: Primary aldosteronism disrupts its usual renin control of aldosterone.

• Addison's diseaseRelated: Its activation raises renin when aldosterone deficiency causes salt loss and reduced circulating volume.

• FludrocortisoneRelated: Fludrocortisone mimics aldosterone, the system’s main mineralocorticoid hormone.

• Loop diureticRelated: The fluid loss induced by loop diuretics can activate this compensatory system.

• Angiotensin IINarrower topic: Angiotensin II is its principal vasoconstrictor and aldosterone-stimulating effector.

• Heart failure with reduced ejection fractionRelated: Its activation promotes fluid retention and remodeling that worsen chronic heart failure.

• SpironolactoneNarrower topic: Aldosterone, the hormone spironolactone opposes, is the system’s downstream effector.

• CaptoprilNarrower topic: Captopril acts within this system by preventing angiotensin II formation.

• NephrologyRelated: Its kidney effects explain why blocking it can protect against proteinuric kidney disease.

• Sacubitril/valsartanNarrower topic: Valsartan counteracts a pathway that can worsen heart failure through vasoconstriction and fluid retention.

• Liddle syndromeRelated: Sodium retention suppresses renin and aldosterone, distinguishing Liddle syndrome from hormone-driven causes.

• Bartter syndromeRelated: Salt loss and reduced circulating volume activate this system, raising renin and aldosterone.

• Gitelman syndromeRelated: Salt loss activates this system, increasing aldosterone-driven potassium and hydrogen loss.

• Kidney failureRelated: Kidney injury can alter this system and compound blood-pressure and fluid problems.

• LisinoprilNarrower topic: Lisinopril alters this system’s signaling to reduce vascular constriction and fluid retention.

• LosartanNarrower topic: Losartan interrupts one of this system’s main blood-pressure pathways.

• Angiotensin INarrower topic: Angiotensin I is a short-lived intermediate in this regulatory network.

• EnalaprilNarrower topic: Enalapril changes blood pressure by interrupting this regulatory pathway.

• FurosemideRelated: Fluid loss from furosemide can activate this system and promote compensatory salt retention.

• HydrochlorothiazideRelated: Reduced circulating volume can activate this system during treatment.

• Hypertensive heart diseaseRelated: Its activation can sustain hypertension and promote cardiac growth and fibrosis.

• ValsartanNarrower topic: Valsartan acts on this system's signaling pathway to reduce vascular and hormonal pressure effects.

• BisoprololRelated: Blocking renal beta-1 receptors can reduce renin release and influence this system.

• HydralazineRelated: Hydralazine can provoke renin release as the body responds to reduced arterial pressure.

• HyperaldosteronismRelated: Its signals regulate aldosterone secretion, though primary disease can suppress renin.

• RamiprilNarrower topic: Ramipril interrupts one of this system’s main pathways for raising blood pressure.